Effectiveness and risk with LapDap

Slides:



Advertisements
Similar presentations
MICS3 Data Analysis and Report Writing
Advertisements

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Longitudinal trial of chloroquine monotherapy and combination therapy for uncomplicated falciparum malaria in children in Blantyre, Malawi Presenter: Patricia.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Caroline Lynch & Jim Tulloch June 2014 Synthesis of current evidence on the multiple causes of malaria drug resistance.
Antimicrobial resistance “One health fits all”
Malaria treatment. Dr abdulrahman al shaikh.. Introduction million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.
World Health Organization
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.
FUTURE RESEARCH ON MALARIA: Towards a malaria-free country Emiliana Tjitra National Institute of Health Research and Development Jakarta, 30 April 2015.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
WHO Traditional Medicine Strategy and Guidelines Dr Arvind Mathur MD, DHA, DNB Cluster Coordinator Family & Community Health WHO-India World Health Organisation.
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards.
Technology & Public Health – experiences with malaria control AFRICANDO – 20 JULY 2006 Richard Tren.
Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.
ABSTRACT Malaria is a mosquito –borne infectious disease of humans caused by the bite of a female anopheles mosquito. The disease is prevalent in tropical.
1 Towards the future: medicines and the elimination of malaria Defeating Malaria Together Timothy N.C. Wells PhD ScD Chief Scientific Officer MMV.
T e c h n i c a l S e m i n a r s Malaria Overview Overview Case DefinitionCase Definition Kills Quickly Malaria Risk HighHigh Low How to Assess ClassificationLowHow.
MALARIA TRACK SESSION SUMMARIES_ICIUM 2011 TEAM MEMBERS: EVELYN ANSAH, KOJO YEBOAH-ANTWI, CHARLES EZENDUKA, DAVID OFORI-ADJEI.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Biomedical Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Quality Control Approaches for Essential Medicines “Good Intentions – Bad Drugs” The World Bank March 10, 2005.
Malaria Case management KPA conference. Presentation outline  Introduction  National malaria strategy  Case management targets  AMFm subsidy  The.
Personal Protection Against Malaria avoidance of exposure to mosquitoes at their peak feeding times (usually dusk and dawn) and throughout the night use.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
GLUCOSE-6-PHOSPATE DEHYDROGENASE DEFICIENCY GENETICS PRESENTATION BY GROUP A2(MD2) WINDSOR UNIVERSITY SCHOOL OF MEDICINE. IVEREN,FOLA,FLOURISH, ALLISON,
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
A R ETROSPECTIVE R EVIEW OF THE IMPLEMENTATION OF A VITAMIN D SUPPLEMENTATION POLICY IN CHILDREN WITH CHRONIC RENAL IMPAIRMENT. Sandra H. Geraghty, Clinical.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Homework 1 Part 2. Drug Resistance and Malaria Download “Drug Resistance and Malaria” by Peter Bloland, published by the World Health Organization:
Sayed Ali Mus POST GRADUATES-BATCH 6 FACULTY OF MEDICAL LABORATORY SCIENCES PARASITOLOGY DEPARTMENT ALNEELIN UNIVERSITY March 2015 Symposium on: Advances.
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,
Genotype-directed dosing for Efavirenz
Seasonal Malaria Chemoprevention: WHO Policy and Perspectives
The Stages of a Clinical Trial
Efficacy and Safety of Medicines
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Hindu College of PG Courses
Copyright © 2016 by Mosby, an imprint of Elsevier Inc.
Clinical Trials — A Closer Look
8. Causality assessment:
Causes of malaria in human Plasmodium falciparum Plasmodium vivax Plasmodium malariae Plasmodium ovale.
Prescribing.
Change in malaria treatment policy: A study of its immediate effects on hospital malaria drug management, utilization of hospital facilities and prescription.
AFSAR FATHIMA M.Pharm.
Seasonal Malaria Chemoprevention: “Rebound”
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
Malaria Prevention Dietsmann HSE Awareness Campaign.
Pharmacovigilance (PV)
Clinical audit 2017/18 National Results
Innovation & the Pharmaceutical Research & Development Industry
Clinical audit 2017/18 National Results
Quality Problems with Antimalarials
Essential Drugs and Medicines Policy
PROSES TERAPI DAN PERMASALAHANNYA
Anthony D Harries Ministry of Health, Malawi
Essential Drugs and Medicines Policy
Prescription-only vs. over-the-counter medicines
Current Evaluation Process
Audit of Demand Management Strategies in York
Recommended clinical guideline for the management of Kawasaki disease in the UK. Since risk scores for IVIG resistance perform sub-optimally in non-Japanese.
Presentation transcript:

Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards

What is LapDap Two very old drugs, combined for a new indication: Malaria Chlorproguanil An little used anti-malarial Dapsone An anti-leprotic and immunomodulator

Mystic Herbal balm ? Mystic Herbal balm ?

Is the combination effective in malaria? Yes, in studies of nearly 3000 African subjects (nearly all children) published in the Lancet and submitted to the UK MHRA, it is very effective Also in sulfadoxine-pyrimethamine resistance In Asia there is considerable resistance developed The time window for effective use in Africa may be limited It is also cheap: around the same price as chloroquine

Is it safe? Considerable inter-individual variability in plasma levels of both drugs ? Genetic polymorphisms No PK studies in elderly or diseased Limited previous experience in children Dapsone dose about 2x its use in leprosy, and close to toxic dose Limited experience with chlorproguanil, but no major problems

But….. Dapsone causes: Variably severe haemolysis in people with G6PD deficiency >20% of Africans have the deficiency to some extent They will not know they have it unless tested Methaemaglobinaemia, with reduced oxygen carryng capacity Malaria also causes haemolysis!!

Registration of LapDap First registered in UK, now in <20 African countries UK conditions are: Prescription only Contraindicated in G6PD There is no serious restriction on availability imposed in Africa About 50% of patients who treat themselves for malaria do not have the disease How will patients know they are G6PD deficient anyway

”Pull out, Bettyl Pull out...You’ve hit on artery”

Review of Safety of Chlorproguanil/Dapsone WHO Technical Consultation Geneva, 1-2July, 2004 Publ. March 2005 The executive summary only

Chlorproguanil/Dapsone Should be used only if the diagnosis of malaria is confirmed. Should only be used after anaemia have been excluded by a reliable clinical or laboratory test and G6PD deficiency by a reliable laboratory test. The diagnosis of methaemoglobinemia is less important

Chlorproguanil/Dapsone In areas where G6PD deficiency is prevalent, it is important before using CPG-DDS to know the level of anaemia and the G6PD status of the patient. If appropriate tests are not possible, an alternative antimalarial medicine should be used. If there is no suitable alternative, CPG-DDS should be used taking into account all the risks associated with this medicine.

Chlorproguanil/Dapsone These recommendations are to be reconsidered when more data becomes available from pharmacovigilance and active post-marketing surveillance. Safety studies have yet to be done!

Implications What is its safety on repeated use? Is this a good combination with artemesinin derivatives? For: Cheap and effective Against: Safety, as we assess it now